Lenvervimab
Humanized | |
|---|---|
| Target | hepatitis B virus surface antigen |
| Clinical data | |
| Other names | GC1102 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Lenvervimab (
INN;[1] development code GC1102) is a monoclonal antibody that is being investigated for hepatitis B.[2]
This drug is being developed by GC Pharma. As of 2018[update], lenvervimab is undergoing
III
trials.
References
- ^ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 118" (PDF). WHO Drug Information. 31 (4).
- PMID 32790777.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |